AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 15321210
Drug: Bupivacaine 10
RxNorm normalized name: BUPivacaine 100 mg parenteral implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine 10 mg (4 ml of 0.25% ‐ test) followed by bupivacaine 20 mg (8 ml of 0.25% ‐ loading)
Trial: 29266092
Drug: FEDWASH (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FEDWASH (30 g CHO·h during SS + WASH during TT)
Trial: 29266092
Drug: FEDPLA (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FEDPLA (30 g CHO·h during SS + placebo wash during TT)
Trial: 28419170
Drug: Couple-based cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Couple-based cognitive behaviour therapy (CBT)
Trial: 28419170
Drug: One-to-one cognitive
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One-to-one cognitive behaviour therapy (CBT)
Trial: 23974823
Drug: Concomitant TMZ
RxNorm normalized name: TMZ
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Concomitant TMZ (75 mg/m²/day) during the first and last weeks of RT in the RT-TMZ-10.00 study
Trial: 23974823
Drug: Concomitant TMZ
RxNorm normalized name: TMZ
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Concomitant TMZ (75 mg/m²/day) during all weeks of RT in the RT-TMZ-01.04 trial
Trial: 23974823
Drug: Adjuvant TMZ
RxNorm normalized name: TMZ
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Adjuvant TMZ (200 mg/m²) administered for 5 days every 28 days
Trial: 15990745
Drug: Chromium picolinate
RxNorm normalized name: Chromium Picolinate
DrugBank: Chromium picolinate (DB11255)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chromium picolinate (CrPic) 1000 microg daily for 3 months
Trial: 8720373
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil (1.8 g of n-3 PUFA)
Trial: 2036564
Drug: Diluted media
RxNorm normalized name: Stellaria media extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diluted media (150 mgI/ml)
Trial: 7055525
Drug: Extradural morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extradural morphine (4mg before skin incision and an additional 4mg at skin closure)
Trial: 28533226
Drug: Chemotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy with concurrent trastuzumab (Arm C)
Trial: 28533226
Drug: Chemotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy with sequential trastuzumab (Arm B)
Trial: 25643353
Drug: Low-iodine group
RxNorm normalized name: Iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Low-iodine group (270 mg I/mL, 100 kVp) with iterative reconstruction (IR)
Trial: 25643353
Drug: High-iodine group
RxNorm normalized name: Iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High-iodine group (370 mg I/mL, 120 kVp)
Trial: 22987136
Drug: Amiodarone (group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amiodarone (group A; 219 patients) - intravenous infusion (15 mg/kg for 48 h postoperatively) after a loading dose (5 mg/kg)
Trial: 22987136
Drug: Magnesium sulfate
RxNorm normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Magnesium sulfate (group M; 219 patients) - loading dose (80 mg/kg over 30 min preoperatively) and then intravenous infusion (8 mg/kg/h for 48 h)
Trial: 17523328
Drug: Synbiotic 2000
RxNorm normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Synbiotic 2000 (lactobacilli preparations with 10^10 CFU and prebiotics)
Trial: 11495873
Drug: Diclofenac 50
RxNorm normalized name: DICLOFENAC 50MG/MISOPROSTOL 200MCG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofenac 50 mg po
Trial: 11495873
Drug: Diazepam 10
RxNorm normalized name: diazepam 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam 10 mg po
Trial: 9706735
Drug: Topiramate (doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topiramate (doses not specified)
Trial: 9706735
Drug: Topiramate (high
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topiramate (high doses)
Trial: 9706735
Drug: Topiramate (doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topiramate (doses beyond 600 mg/day)
Trial: 7817799
Drug: Sodium fluoride
RxNorm normalized name: Sodium Fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium fluoride treatment (60 mg NaF/day for 1-2 years)
Trial: 7817799
Drug: Osteoporotic bone
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Osteoporotic bone before fluoride treatment
Trial: 24364538
Drug: Intranasal users
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal users
Trial: 17333787
Drug: Prednisolone, 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone, 30 mg/day for 10 days
Trial: 17333787
Drug: Anti-tuberculosis (TB)
RxNorm normalized name: Mycobacterium tuberculosis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-tuberculosis (TB) drugs for 6 months
Trial: 10929163
Drug: Zinc acetate
RxNorm normalized name: Zinc Acetate
DrugBank: Zinc acetate (DB14487)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Zinc acetate lozenges (12.8 mg)
Trial: 1396796
Drug: Omnipaque (iohexol)
RxNorm normalized name: Iohexol
DrugBank: Iohexol (DB01362)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Omnipaque (iohexol) 350 mgI/ml
Trial: 1396796
Drug: Telebrix (sodium-meglumine-ioxithalamate)
RxNorm normalized name: Celebrex
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Telebrix (sodium-meglumine-ioxithalamate) 350 mgI/ml
Trial: 2861365
Drug: Biodegradable polylactide‐glycolide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biodegradable polylactide‐glycolide copolymer implants
Trial: 2861365
Drug: Conventional metallic
RxNorm normalized name: Aluminum metal
DrugBank: Aluminium (DB01370)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional metallic implants
Trial: 28820746
Drug: D-Cycloserine (125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D-Cycloserine (125 mg) administered pre-exposure therapy
Trial: 28820746
Drug: D-Cycloserine (125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D-Cycloserine (125 mg) administered post-exposure therapy
Trial: 25403903
Drug: Denosumab 60
RxNorm normalized name: denosumab 60 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Denosumab 60 mg subcutaneously every 6 months for 3 years
Trial: 25403903
Drug: Denosumab 60
RxNorm normalized name: denosumab 60 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Denosumab 60 mg subcutaneously every 6 months for 1 year (cross-over group)
Trial: 24771706
Drug: Wrist self-monitoring
RxNorm normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Wrist self-monitoring device with daily BP measurement for 24 weeks
Trial: 14769778
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg 5‐MTHF
Trial: 14747389
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg folic acid
Trial: 12365087
Drug: Single treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single treatment (ACE inhibitor, beta‐blocking drug or ARB)
Trial: 12365087
Drug: Single treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single treatment (calcium channel‐blocking drug or thiazide diuretic)
Trial: 12365087
Drug: Fixed combination
RxNorm normalized name: Progestogens and estrogens, fixed combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed combination therapy (one drug from group 1 and one drug from group 2)
Trial: 12365087
Drug: Initial monotherapy
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Initial monotherapy maintained alone or in combination
Trial: 9677171
Drug: STD treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: STD treatment (directly observed, single oral dose)
Trial: 9677171
Drug: Control arm
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control arm received anthelminthic and iron-folate (directly observed, single oral dose)
Trial: 2688238
Drug: Porcine insulin
RxNorm normalized name: Porcine insulin
DrugBank: Insulin pork (DB00071)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Porcine insulin (PI)
Trial: 31870314
Drug: Multicomponent exercise
RxNorm normalized name: meningococcus B, multicomponent vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multicomponent exercise intervention (twice a week for 16 weeks, 45-60 minutes each session)
Trial: 19690548
Drug: Gemcitabine (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine (1000 mg m(‐2) over 30 min on days 1, 8, and 15, every 4 weeks for 3 cycles)
Trial: 16803844
Drug: S-1 alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-1 alone (2 weeks of treatment and 1 week of rest for 6 months, followed by 2 weeks of treatment and 2 weeks of rest for 6 months)
Trial: 16803844
Drug: S-1 plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-1 plus PSK (the same regimen of S-1 plus daily PSK for 12 months)
Trial: 12717216
Drug: Sirolimus plus
RxNorm normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Sirolimus plus steroids (SRL+ST)
Trial: 12717216
Drug: Sirolimus with
RxNorm normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Sirolimus with cyclosporine A plus steroids (SRL+CsA+ST)
Trial: 9283538
Drug: Conscious sedation
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conscious sedation with combined intravenous midazolam, morphine, and promethazine, plus deep sedation with etomidate
Trial: 9283538
Drug: Propofol anesthesia
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol anesthesia administered by an attending anesthesiologist
Trial: 27131407
Drug: Amaranth extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amaranth extract (2 g as single dose)
Trial: 21142821
Drug: Tablets with
RxNorm normalized name: Aconitum napellus/Evening Trumpetflower/Onion/Zinc Gluconate 6 X-6 X-6 X-2 X Sublingual Tablet [HYLAND'S COLD TABLETS WITH ZINC]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets with resinate (dextromethorphan loaded into Amberlite IRP-69 resin)
Trial: 21142821
Drug: Tablets with
RxNorm normalized name: Aconitum napellus/Evening Trumpetflower/Onion/Zinc Gluconate 6 X-6 X-6 X-2 X Sublingual Tablet [HYLAND'S COLD TABLETS WITH ZINC]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets with physical mixture (dextromethorphan physically mixed with resin)
Trial: 21142821
Drug: Tablets with
RxNorm normalized name: Aconitum napellus/Evening Trumpetflower/Onion/Zinc Gluconate 6 X-6 X-6 X-2 X Sublingual Tablet [HYLAND'S COLD TABLETS WITH ZINC]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets with resinate
Trial: 21142821
Drug: Tablets with
RxNorm normalized name: Aconitum napellus/Evening Trumpetflower/Onion/Zinc Gluconate 6 X-6 X-6 X-2 X Sublingual Tablet [HYLAND'S COLD TABLETS WITH ZINC]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets with physical mixture
Trial: 21142821
Drug: Both tablets
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both tablets (resinate and physical mixture)
Trial: 12856119
Drug: Intravenous teicoplanin
RxNorm normalized name: teicoplanin
DrugBank: Teicoplanin (DB06149)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous teicoplanin (6 mg/kg per 12 h for 48 h, then 6 mg/kg daily)
Trial: 12856119
Drug: Subcutaneous teicoplanin
RxNorm normalized name: teicoplanin
DrugBank: Teicoplanin (DB06149)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous teicoplanin (30-min administration)
Trial: 12856119
Drug: Subcutaneous teicoplanin
RxNorm normalized name: teicoplanin
DrugBank: Teicoplanin (DB06149)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous teicoplanin
Trial: 1835223
Drug: Intravenous teicoplanin
RxNorm normalized name: teicoplanin
DrugBank: Teicoplanin (DB06149)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous teicoplanin
Trial: 1780722
Drug: Gallium arsenide
RxNorm normalized name: GALLIUM ARSENIDE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gallium arsenide laser treatment with standard conservative treatment
Trial: 1780722
Drug: Placebo laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo laser treatment with standard conservative treatment
Trial: 28776304
Drug: Education about
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Education about oral mucositis prevention, including training and Patient Education Booklet
Trial: 28776304
Drug: Education about
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Education about oral mucositis prevention
Trial: 28027413
Drug: Omega 3
RxNorm normalized name: omega 3,6
DrugBank: Capsaicin (DB06774)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Omega 3 (1 gm three times daily for 3 months)
Trial: 28027413
Drug: Dexamethasone (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (1.5 ml) and hyaluronidase (1500 IU) mixed with lignocaine (biweekly for 6 weeks) and placebo (for 3 months)
Trial: 26482279
Drug: Lenvatinib plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lenvatinib plus everolimus (18 mg/day and 5 mg/day)
Trial: 26482279
Drug: Single-agent lenvatinib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-agent lenvatinib (24 mg/day)
Trial: 26482279
Drug: Single-agent everolimus
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Single-agent everolimus (10 mg/day)
Trial: 22827783
Drug: Methimazole (MMI)
RxNorm normalized name: Methimazole
DrugBank: Methimazole (DB00763)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methimazole (MMI) treatment
Trial: 22827783
Drug: Radioiodine (RAI)
RxNorm normalized name: Radioiodine
DrugBank: Iodide I-131 (DB09293)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radioiodine (RAI) treatment with thyroxine
Trial: 17700991
Drug: Clazosentan 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clazosentan 0.2 mg/kg/h
Trial: 10599904
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg doxycycline daily for 14 days
Trial: 1785703
Drug: 30 ml
RxNorm normalized name: Vial M/T 30 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 ml of 0.5 M sodium citrate
Trial: 29653858
Drug: rhNGF 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhNGF 10 μg/ml
Trial: 29653858
Drug: rhNGF 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhNGF 20 μg/ml
Trial: 12032038
Drug: Epidural morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural morphine (EM; 17 mL of 2% lidocaine plus 2 mg of morphine)
Trial: 12032038
Drug: IV morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV morphine (IVM; 17 mL of 2% lidocaine plus 0.2 mL of normal saline, followed by IVM 2 mg IV)
Trial: 12032038
Drug: Control (17
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (17 mL of 2% lidocaine plus 0.2 mL of normal saline, followed by 0.2 mL of normal saline IV)
Trial: 31739848
Drug: Technology assisted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Technology assisted sleep extension intervention (wearable sleep tracker, smartphone application, weekly didactic lessons, brief telephone coaching)
Trial: 29851204
Drug: Vesatolimod (1-,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vesatolimod (1-, 2-, or 4-mg) once weekly for 12 weeks
Trial: 31874050
Drug: Placebo once
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo once weekly for 12 weeks
Trial: 29851204
Drug: Tenofovir disoproxil
RxNorm normalized name: Tenofovir Disoproxil
DrugBank: Tenofovir disoproxil (DB00300)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tenofovir disoproxil fumarate (300-mg daily) for 48 weeks
Trial: 29231362
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy group (scraping therapy + xuanfei zhisou decoction)
Trial: 29231362
Drug: Chinese herbal
RxNorm normalized name: GINGER 28 mg in 100 mL TOPICAL OIL [Pain Relief Honzo Seika Chinese Herbal Aroma Oil]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chinese herbal medicine group (xuanfei zhisou decoction)
Trial: 25042213
Drug: QUIT intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QUIT intervention of brief clinician advice and up to two drug-use health telephone sessions
Trial: 17597256
Drug: Intravenous morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous morphine (0.1 mg/kg, maximum 5 mg)
Trial: 11720695
Drug: Nortriptyline or
RxNorm normalized name: nortriptyline Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nortriptyline or Paroxetine (12 weeks treatment)
Trial: 9497787
Drug: NG-monomethyl-L-arginine, 1-4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NG-monomethyl-L-arginine, 1-4 mumol/min
Trial: 21444270
Drug: Mouthrinse and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mouthrinse and antiseptic (as chlorhexidine agents)
Trial: 7100223
Drug: (-)eburnamonine (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (-)eburnamonine (100 mg infusion)
Trial: 7100223
Drug: Chronic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chronic treatment with (-)eburnamonine (oral route)
Trial: 20015193
Drug: Combined Parent
RxNorm normalized name: C.I. direct red 28 parent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined Parent Training and Child Treatment (PT+CT)
Trial: 18061705
Drug: Vaginal misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vaginal misoprostol 400 mcg every 3 h
Trial: 18061705
Drug: Hypertonic saline
RxNorm normalized name: ENTSOL Hypertonic Saline Nasal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypertonic saline and d-cloprostenol 2.5 mg/h
Trial: 11401178
Drug: Intravenous cilomilast
RxNorm normalized name: CILOMILAST
DrugBank: Cilomilast (DB03849)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous cilomilast 1, 2, and 4 mg
Trial: 11401178
Drug: Oral cilomilast
RxNorm normalized name: CILOMILAST
DrugBank: Cilomilast (DB03849)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral cilomilast 15 mg
Trial: 11401178
Drug: Oral cilomilast
RxNorm normalized name: CILOMILAST
DrugBank: Cilomilast (DB03849)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral cilomilast 15 mg in fed subjects
Trial: 11401178
Drug: Oral cilomilast
RxNorm normalized name: CILOMILAST
DrugBank: Cilomilast (DB03849)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral cilomilast 15 mg in fasted subjects
Trial: 11401178
Drug: Oral cilomilast
RxNorm normalized name: CILOMILAST
DrugBank: Cilomilast (DB03849)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral cilomilast 15 mg with different dosing times
Trial: 11401178
Drug: Oral cilomilast
RxNorm normalized name: CILOMILAST
DrugBank: Cilomilast (DB03849)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral cilomilast 15 mg with aluminum hydroxide‐magnesium hydroxide
Trial: 9566385
Drug: Estrogen-replacement therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estrogen-replacement therapy
Trial: 3190163
Drug: Moderate dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate dose of vitamin C (200 mg/day)
Trial: 3190163
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose of vitamin C (2,000 mg/day)
Trial: 26777745
Drug: Microbial cell
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Microbial cell preparation (treatment)
Trial: 23842100
Drug: Intravitreal FCFD4514S
RxNorm normalized name: Dexamethasone Intravitreal Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal FCFD4514S (maximum tolerated dose: 10 mg)
Trial: 15639065
Drug: Cerazette (75-microg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cerazette (75-microg desogestrel-only contraceptive pill) taken for 56 days with three tablets taken 12 hours late
Trial: 10793299
Drug: A cocktail
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A cocktail of daily doses of 6 g of aged garlic extract, 4-6 g of vitamin C, and 800 to 1200 IU of vitamin E
Trial: 10793299
Drug: Nutritional antioxidant
RxNorm normalized name: antioxidant 119
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutritional antioxidant supplements, hydroxyl radical scavengers, and iron‐binding agents
Trial: 2072407
Drug: Radiotherapy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiotherapy plus tamoxifen (30 mg daily for 48 weeks)
Trial: 6849755
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg methylprednisolone (Solu‐Medrol)
Trial: 6849755
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg naloxone (Nalonee)
Trial: 31420399
Drug: SensiumVitals monitoring
RxNorm normalized name: iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SensiumVitals monitoring system (wearable wireless patch)
Trial: 27586837
Drug: Control (1.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (1.8 g leucine, n = 7)
Trial: 27586837
Drug: Leucine (3.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leucine (3.5 g leucine, n = 8)